FQ
SGMO

First Quadrant’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

First Quadrant’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-146
Closed -$2K – 605
2020
Q4 		$2K Buy
+146
New +$1.71K ﹤0.01% 573
2018
Q2 		– Sell
-1,556
Closed -$30K – 835
2018
Q1 		$30K Buy
+1,556
New +$33.3K ﹤0.01% 766

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

First Quadrant's SGMO Position: Q1 2021 in Review

First Quadrant sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 146 shares — an estimated $2K sold.

First Quadrant first reported a position in SGMO in Q1 2018 and held it in 2 quarters. The position peaked at $30K in Q1 2018. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

  • First Quadrant reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
  • First Quadrant sold 146 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $2K.
  • First Quadrant first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 2 quarters.
  • First Quadrant's SANGAMO THERAPEUTICS INC position peaked at $30K in Q1 2018.
  • 203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on First Quadrant's 13F filing for Q1 2021, filed 27 Apr 2021.